Faculty Collaboration Database

1. Lawton CA, Glisch C, Byhardt RW, Sehring S, Hartz A, Cox JD: Extended field radiation for prostate carcinoma with para-aortic lymph node metastasis. Am J Clin Oncol 9:302-306,l986.

2. Lawton CA, Barber-Derus S, Murray KJ, Casper JT, Ash RC, Gillin MT, Wilson JF: Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant. Int J Radiat Oncol Biol Phys 17:319-322, 1989.

3. Camitta B, Ash R, Menitove J, Murray K, Lawton C, Hunter J, Casper J: Bone marrow transplantation for children with severe aplastic anemia: Use of alternative donors. Blood 74:1852-1857, 1989.

4. Ash RC, Casper J, Menitove J, Chitambar C, Hansen R, Lum L, Lawton C, Murray K, Hunter J, Anderson T, Camitta B: Evolving role of the closely HLA-matched unrelated marrow donor: HLA matching considerations for alternative donor transplantation. Bone Marrow Transplantation: Current Controversies (Gale RP, Champlin R, Liss AR, Eds.) New York, NY, pp. 629-640, 1989.

5. Ash RC, Casper J, Chitambar C, Hansen R, Bunin N, Truitt R, Lawton CA, Murray K, Hunter J, Baxter-Lowe L, Gottschall JL, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. New Eng J Med 322:485-494, 1990.

6. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SRL, Rubin P: Long term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Rad Onc Biol Phys 21:935-939, 1991.

7. Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT, Moulder JE: Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer 67:2795-2800, 1991.

8. Weissman DE, Janjan NA, Erickson B, Wilson JF, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA, Rousey SR: Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neuro-Oncol 11:235-239, 1991.

9. Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, Ash, RC: Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 9:1848-1859, 1991.

10. Bunin NJ, Casper JT, Lawton C, Murray K, Camitta BM, Greenwood M, Geil J, Ash RC: Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings. Bone Marrow Transplantation 9:119-122, 1992.

11. Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF: Is long term survival possible with external beam irradiation for Stage D1 adenocarcinoma of the prostate? Cancer 69:2761-2766, 1992.

12. Lawton CA, Barber-Derus SW, Murray KJ, Cohen E, Ash RC, Moulder J: Influence of renal shielding on the incidence of late renal dysfunction associated with bone marrow transplantation in adult patients. Int J Rad Oncol Biol Phys 23:681-686, 1992.

13. Cohen EP, Lawton CA, Moulder JE, Becker CG, Ash RC: The clinical course of late onset bone marrow transplant nephropathy. Nephron 64:626-635, 1993.

14. Lawton CA, Fish BL, Moulder JE: Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation. Int J Rad Onc Biol Phys 28:883-889, 1994.

15. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar C, Anderson T, Flomenberg N: Impact of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980-1987, 1994.

16. Lawton CA, Cantrell JE, Derus SWB, Murray KJ, Byhardt RW, Wilson JF: Are racial differences in clinical stage and survival in patients with prostate cancer explained by differences in presenting symptoms? Radiology 192:37-40, 1994.

17. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Keever C, Drobyski W, Horowitz M, Flomenberg N, Ash R: Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 85:2354-2363, 1995.

18. Pilepich MV, Caplan RJ, Al-Sarraf M, John M, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Cox JD: Androgen suppression with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology, 45:4 616-623, 1995.

19. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, Drobyski W, Ash R, Horowitz M, Camitta B, Lawton C, Garbrecht F, Gottschall J: Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplantation,16:271-275, 1995.

20. Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, and Cella D: RTOG's first quality of life study - RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Rad Oncol Biol Phys, 33:4, 901-906, 1995.

21. Cohen EP, Lawton CA, and Moulder JE: Bone marrow transplant nephropathy - Radiation nephritis revisited. Nephron 70:217-222, 1995.

22. Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, Breitmeyer J, Alger ME, and Borden EC: Recombinant human interferon-beta (r-hIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. Journal of Interferon and Cytokine Research, 16:891-902, 1/96.

23. Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD, and Rotman M: Results of a phase II trial of external beam radiation with Etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). Int J Rad Oncol Biol Phys, 36:673-680, 1996.

24. Gore EM, Lipchik RJ, Ash RC, Lawton CA,Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Rad Oncol Biol Phys, 36:67-75, 1996.

25. Margolis D, Camitta B, Pietryga D, Keever-Taylor C, Kupst M, French J, Murray K, Lawton C, Truitt R, Pierce K, Garbrecht F, Flomenberg N, Baxter-Lowe LA, Casper J, Unrelated donor bone marrow transplantation to treat severe aplastic anemia in children and young adults. British Jnl Hem 94:65-77, 1996.

26. Grignon D, Caplan R, Sarkar F, Lawton C, Forman J, Mesic J, Fu K, Abrams R: p53 Status and Prognosis of Locally Advanced Prostatic Adenocarcinoma: A Study Based on RTOG 86-10. Journal National Cancer Institute (NCI) 89:2 158-165, 1997.

27. Lawton CA, Winter K, Byhardt R, Sause WT, et al: Androgen Suppression Plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Results based on a National Prospective Randomized Trial RTOG #85-31). Int J Rad Onc Biol Phy 38:5 931-939, 1997.

28. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A: Phase III trial of androgen suppression using gossrelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy - report of RTOG protocol 85-31. Journal of Clinical Oncology, 15:1013-1021, 1997. Senior author mentoring resident. Paper won ASTRO resident award.

29. Lawton CA, Derus SB, Murray, KJ, Cohen E,Moulder J:Update on Renal Shielding and Incidence of Late Renal Dysfunction Associated with Bone Marrow Transplantation in Adults.Bone Marrow Transplantation, 12:1069-1074,1997.

30. Juckett M, Rowlings P,Hessner M,Keever-Taylor C, Burns W, Camitta B,Casper J,Drobyski W,Hanson G,Horowitz M,Lawton C, Margolis J, Peitrygga D, and Vesole D. T-Cell depleted allogeneic bone marrow transplantation for high risk non-Hodgkin lymphoma:Clinical and molecular follow up. Bone Marrow Transplantation, 21:893-899, 1998.

31. Byhardt R, Scott C, Sause W, Emami B, Komaki R, Fisher B, Lee J, and Lawton C. Response, Toxicity, Failure Patterns and Survival in Five Radiation Therapy Oncology Group (RTOG) Protocols of Sequential and/or Concurrent Chemotherapy and Radiotherapy for Locally Advanced Non-Small Carcinoma of the Lung. Int Jour of Rad Onc Bio Phys 42(3) 469-478, 1998.

32. Watkins Bruner, D., Scott, C., McGowan, D., Lawton, C., Hanks, G., Prestidge, B., Han, S., Gore, E., and Asbell, S. The RTOG Modified Sexual Adjustment Questionnaire: Psychometric Testing in the Prostate Cancer Population. Int Jour of Rad Onc Bio Phys 42(1) #156, 202,1998.

33. Lawton CA, Grignon D, Newhouse J, Schellhammer P, and Kuban D. RSNA Oncodiagnosis Panel: 1997, RadioGraphics. 19:1, 185-203,1999.

34. Movsas B, Scott C, Sause M, Byhardt R, Ritsuko K, Cox J, Johnson D, Lawton C, Dar A., Wasserman T, Roach M, Lee J, and Andras E. The Benefit of Treatment Intensification is Age and Histology-dependent in Patients with Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Quality-Adjusted Survival Analysis of Radiation Therapy Oncology Group (RTOG) Chemo-Radiation Studies. Int J Rad Onc Bio Phys 45:5, 1143-1149, 1999

35. Scott, C., Roach, M., Lawton, C.,, Gallagher, M..Doggett, S., Hanks, G., Coughlin, C: Q-Twist Analysis of Men Treated for Prostate Cancer with Radiotherapy with or without Neoadjuvant Combined Androgen Blockade: Based on Radiation Oncology Group 86-10. l Quality of Life Research 8(7): #48, 568, 1999.

36. Roach M.,Lu J., Pilepich M., Asbell S., Mohiudden M., Terry R., Grignon D., Lawton C., Shipley W., and Cox J. Predicting Long Term Survival, and the Need for Hormonal Therapy: An Analysis of RTOG Prostate Cancer Trials 85-06 through 86-10. Int J Radiation Oncology Biol Phys 47(3):617-627, 2000.

37. Horwitz E, Winter K, Hanks G, Lawton C, Russel A, and Machay M. Subset Analysis of RTOG 85-31 and 86-10 indicate an advantage for long-term versus short-term adjuvant hormones for patients with locally advanced non-metastatic Gleason score 7-10 prostate cancer treated with radiation therapy. Int J Rad Onc Bio Phys 49:4, 947-956, 2001.

38. Lawton CA, Winter K, Murray K, Machay M, Mesic M, Hangs G, Coughlin C, and Pilepich M. Updated results of the phase II RTOG trial 85-31 evaluating the potential benefit of androgen suppression deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Rad Onc Bio Phys 49:4, 937-946, 2001.

39. Juckett M, Cohen E, Keever-Taylor C, Lawton C, Moulder J, and Klein J. Loss of Renal Function Following BMT: An Analysis of Angiotensin Converting Enzyme D/I Polymorphism and Other Clinical Risk Factors. Bone Marrow Transplantation 27:4, 451-456, 2001.

40. Pilepich MV, Winter K, Fu KK, Russell AH, Sause W, Rubin P, Lawton C, Machtay M, and Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Rad Onc Bio Phys 50:5, 1243-1252, 2001.

41. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, et al. Analysis of risk factors for the development of GVHD after T-cell depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility and method of T-cell depletion. Biology of Blood and Bone Marrow Transplantation 7(11), 620-630, 2001.

42. Lawton CA, Winter K, Murray K, Machtay M, et al. Routine long-term androgen suppression following standard radiotherapy improves disease-free survival in men with unfavorable-prognosis prostate cancer compared with relapse-initiated therapy. Evidenced-based Oncology 2002 0, 1-2.

43. Shipley W, Lu J, Pilepich M, Heydon K, Roach M, Wolkov H, Sause W, Rubin P, Lawton C, and Machtay M: The Effect of a Short Course of Neoadjuvant Hormone Treatment on the Response to Subsequent Androgen Suppression in Prostate Cancer Patients who Relapse Following Radiation Therapy: A Secondary Analysis of the Randomized Protocol RTOG 86-10. Int J Radiat Onco Biol Phys, 54:5, 1302-1310, 2002.

44. Hanks GF, Pajak T, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz E, Lawton C, Rosenthal S, Sandler H, and Shipley W. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: RTOG Protocol 92-02. Journ Clin Oncol 21(21) 3972-3978, 2003.

45. Pollack A, Grignon D, Heydon K, Hammond E, Lawton C, et al. Prostate cancer DNA plody and response to salvage hormone therapy after radiotherapy with or without short term total androgen blockade: An analysis of RTOG 86-10 Jour Clin Oncol 21(7):1238-1248, 2003.

46. Roach M, Lu JD, Lawton C, Hsu I-C, Machtay M, Seider MJ et al. A phase III trial comparing whole-pelvic (WP) versus prostate only (PO) radiotherapy and neoadjuvant versus adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 94-13. Jour Clinc Onc 21(10) 1904-1911, 2003.

47. Lawton CA, Hormones and Radiation Therapy in Locally Advanced Adenocarcinoma of the Prostate. Seminars in Rad Onc 13:2, 141-151, April 2003.

48. Pollack A, DeSilvio M, Khor Y, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, et al: Ki-67 Staining is a Strong Predictor of Distant Metastasis and Mortality for Men with Prostate Cancer Treated with Radiotherapy plus Androgen Deprivation: RTOG Trial 92-02. Journ of Clinical Oncology 22:11, 2133-2140, 2004.

49. Pilepich M, Winter K, Lawton C, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma long term results of phase III RTOG 85-31. Int J Rad Onc Biol Phys, 61:5, 1285-1290, 2005.

50. Lawton C, Winter K, Grignon D, and Pilepich M: Androgen Suppression plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Updated Results Based on a National Prospective Randomized Trial, RTOG 85-31). J Clin Oncol 23:4, 800-807, 2005.

51. Li XA, Wang JZ, Jursinic P, Lawton C, and Wang D. Dosimetric advantages of IMRT simultaneous integrated boost for high risk prostate cancer. Int J Rad Onc Biol Phys 61:4, 1251-1257, 2005.

52. Feigenberg S, Lee WR, DeSilvio M, Winter K, PasanskyT, Watkins Bruner D, Lawton C, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Rad Onc Biol Phys 62(4):956-64, 2005.

53. Gillin MT. Dunning BF. Lawton CA. Foley WD. Byhardt RW. Morton G. Baikadi M. Pisansky TT. Michalski JM. Ibbott G. Lopez F. Radiation Therapy Oncology Group. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy. 5(3):152-6, Jul-Sep 2006

54. Lee WR. Bae K. Lawton CA. Gillin MT. Morton G. Firat S. Baikadi M. Kuettel M. Greven K. Sandler H. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 5(4):239-43, Oct-Dec 2006

55. Shipley WU, DeSilvio M, Pilepich M, Roach M III, Mesic JB, Sause WT, Rubin P, and Lawton C. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Rad Onc Biol Phys 64:4, pp 1162-1167, 2006.

56. Abdel-Wahab, B Berkey, A Krishan, T O'Brien, E Hammond, M Roach III, C Lawton, M Pilepich, A Markoe, A Pollack: Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Journal of Clinical Oncology 29:1, 14-20, 2006.

57. Roach M III. DeSilvio M. Valicenti R. Grignon D. Asbell SO. Lawton C. Thomas CR Jr. Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J of Rad Onc, Bio, Phy. 66(3):647-53, 2006.

58. Lee WR, DeSilvio M, Lawton C, Gillin M, et al: A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Int J Rad Onc Bio & Phys 64:3, 804-809, 2006.

59. Lawton CA, DeSilvio M, Lee WR, et al: Results of a phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. (RTOG 98-05) Int J Rad Onc Biol & Phys 67(1):39-47, 2007.

60. Lawton C, DeSilvio M, Roach M, III, et al: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13, with Emphasis on Unexpected Hormone/Radiation Interactions. Int J Rad Onc Bio & Phs 69(3):646-655, 2007.

61. Lee WR. Bae K. Lawton C. Gillin M. Morton G. Firat S. Baikadi M. Kuettel M. Greven K. Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 109(8):1506-12, 2007 Apr 15.

62. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys. 2008 Feb 01;70(2):437-41. PMCID: PMC2917176

63. Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. Br J Radiol. 2008 Jan;81(961):59-68.

64. Wang D, Lawton C. Pelvic lymph node irradiation for prostate cancer: who, why, and when? Semin Radiat Oncol. 2008 Jan;18(1):35-40.

65. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 01;26(4):585-91.

66. TausskyD, Bae K, Bahary J, Roach M III, Lawton C, Shipley W, and Sandler H: Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of RTOG 94-13. Urology 72 (5) 1125-1129, 2008.

67. Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H,Venkatesan V, Lawton C, et al: Ten-year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal Clinical Onc 26:15; 2497-2504, May 2008

68. Li XA, Wang Z Stewart RDJ, Dibiase DJ, Wang D, and Lawton C, Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. The British Journal of Radiology 81:59-68, 2008.

69. Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(1):46-52.

70. Ritter M, Forman J, Kupelian P, Lawton C, Petereit D. Hypofractionation for prostate cancer. Cancer J. 2009;15(1):1-6. PMCID: PMC3039916

71. Lawton C, Michalski J, El-Naqa I, Buyyounouski MD,4 RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer Int J Rad Onc Bio Phy 74:2, 383-387, 2009.

72. Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA. An on-line replanning scheme for interfractional variations. Med Phys. 2008 Aug;35(8):3607-15.

73. Eleanor E Harris, May Abdel-Wahab, Ann E Spangler, Colleen Lawton, and Robert J Amdur: Results of the Association of Directors' of Radiation Oncology Programs (ADROP) Survey of Radiation Oncology Residency Program Directors Int J Rad Onc Biol & Phys 74:2, 327-337, 2009.

74. Peng C, Kainz K, Lawton C, Li XA. A comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer. Med Phys. 2008 Dec;35(12):5619-28.

75. Michalski JM, Roach III M, Merrick G, Anscher M, Beyer, D, Lawton C, Lee WR, Pollack A, Rosenthal S, Vijayakumar and Carroll P: ACR Appropriateness Criteria on External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer. Int J Rad Onc Biol & Phys 74:3, 667-672, 2009.

76. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 01;76(2):361-8. PMCID: PMC2847420

77. Lawton CA, Michalski J, El-Naqa I, Kuban D, et al: Variation in the Definition of Clinical Target Volumes for Pelvic Nodal Conformal Radiation Therapy for Prostate Cancer. Int J Rad Onc Biol & Phys 74:2, 377-382, 2009

78. Ahunbay EE, Peng C, Holmes S, Godley A, Lawton C, Li XA. Online adaptive replanning method for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Aug 01;77(5):1561-72.

79. Parker SM, Olteanu H, VanTuinen P, Lawton C, Schultz C, Christians K, and Fenske T: Folicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. Intern Journ of Hematology 90:5, 616-622, 2009.

80. Roach III M, Lawton CA, Chen J: To treat pelvic lymph nodes or not?: Greater testicular scatter does not explain the results of randomized trials! Journal Clinical Oncology 28:25 450-452, 2010.

81. Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 01;78(5):1314-22. PMCID: PMC2920356

82. Lawton CA, Hunt D, Lee WR, et al: Long Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05) Int J Rad Onc Biol & Phys 81(1) 1-7, 2011.

83. Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 01;79(3):909-14.

84. Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ. Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int. 2011 Jul;108(2 Pt 2):E51-8. PMCID: PMC3062644

85. Peng C, Chen G, Ahunbay E, Wang D, Lawton C, Li XA. Validation of an online replanning technique for prostate adaptive radiotherapy. Phys Med Biol. 2011 Jun 21;56(12):3659-68.

86. Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys. 2011 Jun 01;80(2):445-52. PMCID: PMC2952349

87. Li XA, Liu F, Tai A, Ahunbay E, Chen G, Kelly T, Lawton C, Erickson B. Development of an online adaptive solution to account for inter- and intra-fractional variations. Radiother Oncol. 2011 Sep;100(3):370-4.

88. Philip Prior, Kiran Devisetty, Sergey Tarima, Colleen Lawton, Vladimir Semenenko: Consolidating Risk Estimates for Radiation-Induced Complications in the Individual Rectal Toxicity. Int Jour Rad Onc Biol & Phys. 2011, Oct 22.

89. Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01;81(5):1293-301. PMCID: PMC4675045

90. Eric P Cohen, Manpreet Bedi, Amy A Irving, Elizabeth Jacobs, John Klein, Colleen Lawton, John E Moulder:Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation.Int J Rad Onc Biol & Phys 83(1) 292-296, 2012.

91. Palta JR, Efstathiou JA, Bekelman JE, Mutic S, Bogardus CR, McNutt TR, Gabriel PE, Lawton CA, Zietman AL, Rose CM. Developing a national radiation oncology registry: From acorns to oaks. Pract Radiat Oncol. 2012;2(1):10-7.

92. Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2012 Apr 01;82(5):e795-801.

93. Morrow NV, Lawton CA, Qi XS, Li XA. Impact of computed tomography image quality on image-guided radiation therapy based on soft tissue registration. Int J Radiat Oncol Biol Phys. 2012 Apr 01;82(5):e733-8.

94. Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W Jr, Gaffney D, Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012 Jul 01;83(3):e353-62. PMCID: PMC3904368

95. Jagsi R, Bekelman JE, Brawley OW, Deasy JO, Le QT, Michalski JM, Movsas B, Thomas CR Jr, Lawton CA, Lawrence TS, Hahn SM. A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. Int J Radiat Oncol Biol Phys. 2012 Oct 01;84(2):318-22.

96. Nassif D, Chen RC, Hoffman KE, Kuban DA, Lawton CA, Michalski JM, Potters L, Rose CM, Sandler HM, Suh W, Wall T, Zietman AL, Bekelman JE. National Radiation Oncology Registry: The pilot prostate cancer registry. J Clin Oncol. 2012 Dec;30(34_suppl):267.

97. Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 01;119(11):1999-2004. PMCID: PMC3663874

98. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May;9(3):e90-5. PMCID: PMC3651578

99. Lindsay DP, Kharofa JR, Lawton, CA, Bylow KA, Langenstroer P, See WA, Wang D: Toxicities and survival of elderly patients with muscle-invasive bladder cancer treated with definitive bladder preservation therapy. Int Journ Rad Onc Biol & Phys 87(2), S398 Oct 2013.

100. Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. PMCID: PMC3830691

101. Yang C, Liu F, Ahunbay E, Chang YW, Lawton C, Schultz C, Wang D, Erickson B, Li XA: Combined online and offline adaptive radiation therapy: A dosimetric feasibility study. Practical Radiation Oncology (PRO) 4, Jan/Feb 2014, e75-e83

102. F Liu, E Ahunbay, C Lawton, A Li: Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy. Medical Physics Mar 2014, 41(3)

103. Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M 3rd, Lawton CA, Sandler HM. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15;121(6):844-52. PMCID: PMC4657945

104. Chen G, Noid G, Tai A, Liu F, Lawton C, and Erickson B: Improving CT quality with optimized image parameters for radiation treatment planning and delivery guidance. (Submitted to Physics and Imaging in Radiation Oncology 2016)

105. Liu F, Ahunbay E, Lawton C, Li XA. Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy. Med Phys. 2014 Mar;41(3):031710.

106. Haffty BG, Lawton CA, Sandler H. Watchful waiting-active surveillancein low risk prostate cancer. JAMA Oncology. 1(5):688-9, 2015 Aug 1.

107. Brower JV, Forman JD, Kupelian PA, Petereit DG, Gondi V, Lawton CA, Anger N, Saha S, Chappell R, Ritter MA. Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. Radiother Oncol. 2016 Jan;118(1):99-104. PMCID: PMC4764419

108. Choudhury A Lawton C, et al: MRI guided prostate adaptive radiotherapy - the future is fast approaching Radiotherapy and Oncology. (Accepted to Radiation Oncology 4/16)

109. McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A; MR-Linac consortium. MRI-guided prostate adaptive radiotherapy - A systematic review. Radiotherapy & Oncology., 119(3) 371-380, 2016 May 6.

110. Prior P, Chen X, Botros M, Paulson ES, Lawton C, Erickson B, Li XA. MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers. Physics in Medicine & Biology. 61(10):3819-42, 2016 May 21. PMC/27089554

111. Ates O, Ahunbay EE, Lawton CA, Li A. A Hybrid Adaptive Replanning Approach for Prostate Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E668-E669.

112. Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY. Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Semin Radiat Oncol. 2017 Jan;27(1):11-20.

113. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 Feb 02;376(5):417-428. PMCID: PMC5444881

114. Lukla HR, Lawton CA, et al: Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer (Submitted to European Urology 9/17)

115. Mirhadi AJ, Zhang Q, Harris GE, Lepor H, Grignon D, Peters CA, Rosenthal SA,Zeitzer K, Radwan JS, Lawton CA, et al: Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate Risk Prostate Cancer Patients Treated on NRG Oncology Treated on RTOG 9202. Int Jour Rad Onc Biol & Phys 97:3, 2017, 511-515

116. Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul 01;123(13):2489-2496. PMCID: PMC5474197

117. Lawton CA, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 01;98(2):296-303.

118. Lawton CA, et al: Risk factors for late bowel and bladder toxicities in NRG Oncology RTOG 9202, 9406, 9413 prostate cancer trials for high risk patients: A meta-analysis of physician related toxicities. (In progress)

119. Roach M, III, Moughan J, Lawton CA, et al: A Phase III Randomized Trial Assessing the Impact of the Sequence of Androgen Deprivation Therapy and Radiotherapy Field Size: Long Term Results of NRG Oncology/RTOG 9413. (Submitted 8/17)

120. Roach M, Yan Y, Lawton CA, Hsu IJ, Lustig RA, Jones CU, Rotman M, Zeitzer KL, Werner-Wasik M, Kim H, Thomas CR, Shipley WU, Sandler HM. Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). J Clin Oncol. 2012 Feb 10;30(5_suppl):96.

121. Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, van Herk M, Li XA, Mittauer K, Ritter M, Choudhury A, Tree AC. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? Int J Radiat Oncol Biol Phys. 2018 Feb 01;100(2):361-373.

122. Lawton CAF. Prostate Cancer: Improving the Flow of Research. Radiology. 2018 Apr;287(1):5-9.

123. Borkenhagen J, Eastwood D, Kilari D, See WA, Van Wickle JD, LAWTON CAF, Hall WA. Prognostic Value of Clinical Stage T2 Substages in Prostate Cancer: A National Cancer Database Review. Int J Radiat Oncol Biol Phys. 2017 Oct 01; 99(2): E216-E217.

124. Lukka H, Pugh SL, Bruner D, Bahary JP, LAWTON CA, Efstahiou JA, Kudchadker R, Ponsky LE, Seaward SA, Dayes IS, Gopaul D, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover W, Beyer D, Sandler HM, Kachnic LA. Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP). DOI: 10.1200/jco.2016.34.2_suppl.27 Journal of Clinical Oncology 34, no. 2_suppl (January 10 2016) 27-27.

125. Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Oct 01;102(2):287-295. PMCID: PMC6248906

126. Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW. Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. Adv Radiat Oncol. 2018;3(3):405-411. PMCID: PMC6128023

127. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1504-1515. PMCID: PMC6540797

128. Borkenhagen J, LAWTON C, Hall W; Digital Rectal Exam Remains a Key Prognostic Tool for Prostate Cancer Patients: A National Cancer Database Review; Accepted for Publication in the Journal of the National Comprehensive Cancer Network

129. Kainz K, Lim SN, Chen GP, Lawton CA, Siker ML, Firat S, Robbins JR, Erickson BA, Li A. Initial Clinical Experience with Using an Automated Dose Tracking Tool to Verify Dose Delivery and Trigger Adaptive Replanning. Int J Radiat Oncol Biol Phys. 2017 Oct 99(2); S222-S223.

130. Hall WA, Karrison TG, Rosenthal SA, Amin M, Gomella LG, Purdy J, Sartor O, Michalski M, Garzotto M, Bergom C, Jani A, Lawton C, Simko J, Moore J, Gore E, Lee WR, Nguyen P, Danielson B, Sandler H, Feng F. The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521. Int J Radiat Oncol Biol Phys. 2018 Nov 102(3); S13-S14

131. Hall W, Liu S, Fishbane N, Xu M, Davicioni E, Mahal B, Den R, Dess R, Jackson W, Wong A, Schaeffer E, Karnes R, Carroll P, Nguyen P Lawton C, Spratt D, Feng F. Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment. Int J Radiat Oncol Biol Phys. 2018 Nov 102(3); S98

132. Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA. Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. J Natl Compr Canc Netw. 2019 Jul 01;17(7):829-837.

133. Hall WA, Baran A, Peterson D, Bergom C, LAWTON CAF, Zhang H, Bylund KC, Messing E, Chen Y, Morrow G, Kerns SL. Characterization of the Host Immuno-Inflammatory State in Response to Radiation Therapy and Correlation with Patient Reported Toxicities In Prostate Adenocarcinoma, A Prospective Observational Trial. Int J Radiat Oncol Biol Phys. 2019 Sept 105(1); S114-S115

134. Hagan M, Kapoor R, Michalski J, Sandler H, Movsas B, Chetty I, Lally B, Rengan R, Robinson C, Rimner A, Simone C, Timmerman R, Zelefsky M, DeMarco J, Hamstra D, LAWTON C, Potters L, Valicenti R, Mutic S, Bosch W, Abraham C, Caruthers D, Brame R, Palta JR, Sleeman W, Nalluri J. VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):639-647. PMID: 31983560

135. LAWTON, C. Gray Zone Opinion - Small Cell, Big Problems. Accepted for publication in Int J Radiat Oncol Biol Phys.

136. Ritter MA, Kupelian PA, Petereit DG, Lawton CA, Anger N, Geye H, Chappell RJ, Forman JD. A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer. Pract Radiat Oncol. 2020 Mar 10. pii: S1879-8500(20)30059-X. PMID: 32169590

137. Kamran SC, Zelefsky M, Nguyen PL, Lawton CAF. To Radiate or Not to Radiate-The Challenges of Pelvic Reirradiation. Semin Radiat Oncol. 2020 Jul;30(3):238-241.

138. Lawton CAF. First, Do No Fistulization. Int J Radiat Oncol Biol Phys. 2020 Aug 01;107(5):866.

139. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 01;109(1):174-185. PMCID: PMC7736505

140. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2021 Jan 10;39(2):136-144. PMCID: PMC8189640

141. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M 3rd, Lawton CAF. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol. 2021 Jan;22(1):11-13. PMCID: PMC8882263

142. Chen GP, Tai A, Puckett L, Gore E, Lim S, Keiper T, Johnstone C, Shukla M, LAWTON C, Li XA. Clinical implementation and initial experience of real-time motion tracking with jaws and MLC during helical tomotherapy delivery. Pract Radiat Oncol. 2021 Feb 10;S1879-8500(21)00047-3. PMID: 33578002

143. Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. Pract Radiat Oncol. 2021;11(6):527-533. PMCID: PMC8638529

144. Hall WA, Lawton CAF, coauthors. In Reply to Onal et al. Int J Radiat Oncol Biol Phys. 2021 Jun 01;110(2):620-621.

145. O. Ates E.E. Ahunbay C.A.F. Lawton A. Li. A Hybrid Adaptive Replanning Approach for Prostate Stereotactic Body Radiation Therapy International Journal of Radiation Oncology, Biology, Physics. POSTER VIEWING ABSTRACT| VOLUME 96, ISSUE 2, SUPPLEMENT , E668-E669, OCTOBER 01, 2016.

146. Kainz K, Alvarez JG, Zhong H, Lim S, Ahunbay E, Tai A, Erickson B, Lawton C, Li XA. Use of a DVH overlay technique for quality assurance of deformable image registration-based dose accumulation. Med Phys. 2021 Nov 26.

147. Yun Ooi K, Pereira I, Nagar H, Simcock R, Katz MS, Parker CC, LAWTON C, Saeed H. Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. Clin Transl Radiat Oncol 2021 Nov;31:21-27 PMID: 34522795 PMCID: PMC8424081

148. Bero EH, Rein LE, Banerjee A, Straza MW, Lawton CAF, Schultz CJ, Erickson BA, Siker ML, Hall WA. Characterization of Underrepresented Populations in Modern Era Clinical Trials Involving Radiation Therapy. Pract Radiat Oncol. 2021 Nov-Dec;11(6):453-459

149. DeWeese TL, Beyer D, Gunderson LL, Haffty BG, Harari PM, Lawton CA, Minsky BD, Steinberg ML. The Model of an ASTRO Servant Leader. Int J Radiat Oncol Biol Phys. 2021 Dec 01;111(5):1120-1121.

150. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol. 2020 Nov;4:1228-1238.

151. Shukla UC, Jimenez RB, Jagsi R, Rosenberg AR, Marron JM, Carfang LJ, Lawton CA, Dizon DS, Katz MS. Ethics-Centered Guidelines for Social Media Use by Oncology Professionals: A Call to Action. JCO Oncol Pract. 2022 Aug;18(8):537-540.

152. Bittner NHJ, Cox BW, Davis B, King M, Lawton CAF, Merrick GS, Orio P, Ouhib Z, Rossi P, Showalter T, Small W Jr, Schechter NR. ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. Am J Clin Oncol. 2022 Jun 01;45(6):249-257.

153. Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FY. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 Oct 01;114(2):266-274. PMCID: PMC9444930

154. Park J, Puckett LL, Katsoulakis E, Venkatesulu BP, Kujundzic K, Solanki AA, Movsas B, Simone CB 2nd, Sandler H, Lawton CA, Das P, Wo JY, Buchholz TA, Fisher CM, Harrison LB, Sher DJ, Kapoor R, Chapman CH, Dawes S, Kudner R, Wilson E, Hagan M, Palta J, Kelly MD. Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative. Pract Radiat Oncol. 2022;12(6):468-474.

155. Hall WA, Kishan AU, Hall E, Nagar H, Vesprini D, Paulson E, Van der Heide UA, Lawton CAF, Kerkmeijer LGW, Tree AC. Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology. Front Oncol. 2022;12:962897. PMCID: PMC9484536

156. Camitta B, Ash R, Menitove J, Murray K, Lawton C, Hunter J, Casper J. Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. Blood. 1989 Oct;74(5):1852-7.

157. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990 Feb 22;322(8):485-94.

158. Bunin NJ, Casper JT, Lawton C, Murray K, Camitta BM, Greenwood M, Geil J, Ash RC. Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings. Bone Marrow Transplant. 1992 Feb;9(2):119-22.

159. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Apr 01;83(7):1980-7.

160. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood. 1995 May 01;85(9):2354-63.

161. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995 Aug;16(2):271-5.

162. Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, Cella D. RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Nov 01;33(4):901-6.

163. Margolis D, Camitta B, Pietryga D, Keever-Taylor C, Baxter-Lowe LA, Pierce K, Kupst MJ, French J 3rd, Truitt R, Lawton C, Murray K, Garbrecht F, Flomenberg N, Casper J. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 1996 Jul;94(1):65-72.

164. Lawton C. Node-positive prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1997 Oct 01;39(3):671-2.

165. Zincke H. Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? Cancer. 1992 Dec 01;70(11):2742-3.

166. Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. Hum Gene Ther. 1998 Jan 01;9(1):115-34.

167. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant. 1998 May;21(9):893-9.

168. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998 Oct 01;42(3):469-78.

169. Amjad A, Xu J, Thill D, Lawton C, Hall W, Awan MJ, Shukla M, Erickson BA, Li XA. General and custom deep learning autosegmentation models for organs in head and neck, abdomen, and male pelvis. Med Phys. 2022 Mar;49(3):1686-1700. PMCID: PMC8917093

170. Kainz K, Garcia Alvarez J, Zhong H, Lim S, Ahunbay E, Tai A, Erickson B, Lawton C, Li XA. Use of a DVH overlay technique for quality assurance of deformable image registration-based dose accumulation. Med Phys. 2022 Jan;49(1):611-623.

171. Yun Ooi K, Pereira I, Nagar H, Simcock R, Katz MS, Parker CC, Lawton C, Saeed H. Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. Clin Transl Radiat Oncol. 2021 Nov;31:21-27. PMCID: PMC8424081

172. Spratt DE, Malone S, Roy S, Sun Y, Lawton C. Reply to S. Sundar et al and S. Höcht et al. J Clin Oncol. 2021 Jul 10;39(20):2316-2317.

173. Chen GP, Tai A, Puckett L, Gore E, Lim S, Keiper T, Johnstone C, Shukla M, Lawton C, Li XA. Clinical Implementation and Initial Experience of Real-Time Motion Tracking With Jaws and Multileaf Collimator During Helical Tomotherapy Delivery. Pract Radiat Oncol. 2021;11(5):e486-e495.

174. Suneja G, Mattes MD, Mailhot Vega RB, Escorcia FE, Lawton C, Greenberger J, Kesarwala AH, Spektor A, Vikram B, Deville C, Siker M. Pathways for Recruiting and Retaining Women and Underrepresented Minority Clinicians and Physician Scientists Into the Radiation Oncology Workforce: A Summary of the 2019 ASTRO/NCI Diversity Symposium Session at the ASTRO Annual Meeting Advances in Radiation Oncology. 1 September 2020;5(5):798-803.

175. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 01;50(5):1243-52.

176. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant. 2001;7(11):620-30.

177. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS, Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003 May 15;21(10):1904-11.

178. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 01;21(21):3972-8.

179. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D, Carroll PR. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 Urologic Oncology: Seminars and Original Investigations. November/December 2005;23(6):462-463.

180. Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64.

181. Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006 Mar 01;64(3):804-9.

182. Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999 Dec 01;45(5):1143-9.

183. Roach M 3RD, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000 Jun 01;47(3):617-27.

184. Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, Roach M 3rd, Lawton C, Pilepich M, Markoe A, Pollack A. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol. 2006 Feb;29(1):14-20.

185. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006 Nov 01;66(3):647-53.

186. Hagan M, Kapoor R, Michalski J, Sandler H, Movsas B, Chetty I, Lally B, Rengan R, Robinson C, Rimner A, Simone C, Timmerman R, Zelefsky M, DeMarco J, Hamstra D, Lawton C, Potters L, Valicenti R, Mutic S, Bosch W, Abraham C, Caruthers D, Brame R, Palta JR, Sleeman W, Nalluri J. VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys. 2020 Mar 01;106(3):639-647.

187. Lim SN, Ahunbay EE, Nasief H, Zheng C, Lawton C, Li XA. Indications of Online Adaptive Replanning Based On Organ Deformation. Pract Radiat Oncol. 2020;10(2):e95-e102.

188. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. J Urol. 2019 Mar;201(3):528-534.

189. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol. 2018;8(6):354-360.

190. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018 Oct 11;36(34):JCO1801097. PMCID: PMC6269129

191. Chen GP, Noid G, Tai A, Liu F, Lawton C, Erickson B, Li XA. Improving CT quality with optimized image parameters for radiation treatment planning and delivery guidance Physics and Imaging in Radiation Oncology. October 2017;4:6-11.

192. Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar 01;97(3):511-515. PMCID: PMC5485922

193. McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A, MR-Linac consortium. MRI-guided prostate adaptive radiotherapy - A systematic review. Radiother Oncol. 2016 Jun;119(3):371-80.

194. Prior P, Chen X, Botros M, Paulson ES, Lawton C, Erickson B, Li XA. MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers. Phys Med Biol. 2016 May 21;61(10):3819-42.

195. Michalski JM, Pisansky TM, Lawton CAF, Potters L. Prostate Cancer Clinical Radiation Oncology. 1 January 2015:1038-1095.e18.

196. Lawton C. Choosing wisely. Pract Radiat Oncol. 2014;4(6):356-7.

197. Yang C, Liu F, Ahunbay E, Chang YW, Lawton C, Schultz C, Wang D, Firat S, Erickson B, Li XA. Combined online and offline adaptive radiation therapy: a dosimetric feasibility study. Pract Radiat Oncol. 2014;4(1):e75-83.

198. Liu F, Ahunbay E, Christian R, Lawton C, Wang D, Li X. SU-E-J-11: Characterization of Interfractioanal Anatomical Variations in Post-Operative Radiation Therapy for Prostate Bed. Med Phys. 2012 Jun;39(6Part6):3654.

199. Liu F, Ahunbay E, Lawton C, Li X. SU-E-T-579: Dosimetric Benefits of Online Adaptive Replanning for Post-Operative Radiation Therapy of Prostate Bed. Med Phys. 2012 Jun;39(6Part19):3839.

200. Lawton CA, Cohen EP, Moulder JE. Kidney and adrenal gland Human Radiation Injury. 28 March 2012:841-871.

201. Michalski J, Pisansky TM, Lawton CA, Potters L, Kuban DA. Prostate Cancer Clinical Radiation Oncology: Third Edition. 2012:1037-1097.

202. Michalski JM, Pisansky TM, Lawton CA, Potters L, Kuban DA. Prostate Cancer Clinical Radiation Oncology: Third Edition. October 27, 2011:e51.1-e51.85.

203. Semenenko VA, Chen G, Lawton CA, li XA. SU‐E‐T‐647: Quality of Prostate IMRT Plans Generated Using Biological versus Dose‐Volume Constraints Medical Physics. June 2011;38(6):3638.

204. li XA, Ahunbay E, Peng C, Chen G, Liu F, Lawton C. TH‐C‐BRA‐04: Online Adaptive Radiotherapy for Prostate Cancer: Clinical Implementation and Initial Experience Medical Physics. June 2011;38(6):3852-3853.

205. Holmes S, Peng C, Ahunbay E, Lawton C, Wang D, li X. SU‐GG‐T‐29: Dosimetric Advantages of Online Adaptive Replanning for Radiotherapy of the Prostate and Seminal Vesicles Medical Physics. June 2010;37(6):3190.

206. Peng C, Ahunbay E, Chen G, Lawton C, li X. SU‐FF‐T‐79: Dosimetric QA Tests of An Online Replanning Technique for Prostate Adaptive Radiotherapy Medical Physics. June 2009;36(6):2537.

207. Godley A, Ahunbay E, Lawton C, li X. SU‐FF‐J‐132: Calculation of Cumulative Dose for Daily CT‐Guided Prostate Irradiation Using Deformable Image Registration Medical Physics. June 2009;36(6):2507.

208. Lawton CA, Bae K. In Reply to Drs. Williams and Wiltshire Regarding Update of RTOG 94-13 International Journal of Radiation Oncology Biology Physics. 1 May 2008;71(1):315-316.

209. Lawton CA. In Response to Dr. Millar et al. International Journal of Radiation Oncology Biology Physics. 1 May 2008;71(1):316.

210. Morrow N, Lawton C, li X. WE‐E‐AUD C‐02: Impact of Image Quality On CT Guided Prostate Radiotherapy Medical Physics. June 2008;35(6):2955.

211. Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007 Apr 15;109(8):1506-12.

212. Keane T, Gillatt D, Lawton C, Payne H, Tombal B. Treatment Options in Prostate Cancer Once Primary Therapy Fails European Urology, Supplements. March 2007;6(3):344-353.

213. Gillatt D, Klotz L, Lawton C, Miller K, Payne H. Localised and Locally Advanced Prostate Cancer: Who to Treat and How? European Urology, Supplements. March 2007;6(3):334-343.

214. Peng C, Kainz K, Lawton C, li X. SU‐FF‐J‐45: A Comparison of Daily Megavoltage CT and Ultrasound Imaging Guided Radiation Therapy for Prostate Cancer Medical Physics. June 2007;34(6):2378.

215. Solanki AA, Puckett LL, Kujundzic K, Katsoulakis E, Park J, Kapoor R, Hagan M, Kelly M, Palta J, Ballas LK, DeMarco J, Hoffman KE, Lawton CAF, Michalski J, Potters L, Zelefsky M, Kudner R, Dawes S, Wilson E, Sandler H. Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. Pract Radiat Oncol. 2023;13(2):e149-e165.

216. Hall WA, Lawton CAF. Confirming and Refining Our Existing Postoperative Treatment Strategies Through the Use of Novel Prostate-Specific Positron Emission Tomography (PET) Imaging. Int J Radiat Oncol Biol Phys. 2023 Jan 01;115(1):118-119.

217. Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Feng FY, Pugh SL, Sandler HM, Kachnic LA. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating 2 Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Dec 31.

1. Lawton CA. Book Review on Treatment Methods for Early and Advanced Prostate Cancer, (Accepted to Int J Rad Onc Biol & Phys 12/08)

2. Radiation Oncology Board Review: 2,000 Clinical Questions for Written and Oral Exams, Williams & Wilkins Review, 8/92.

3. Moss' Radiation Oncology: Rationale, Technique, Results, 7th Edition, James D. Cox, M.D., Editor. Lawton, C. A.: Radiation Therapy for Bone Marrow Transplant (Chapter 35), Mosby, St. Louis, p. 937, 1994.

4. Comprehensive Textbook of Genitourinary Oncology, Nicholas J. Vogelzang, M.D., Peter T. Scardino, M.D., William U. Shipley, M.D., and Donald S. Coffey, Ph.D., Editors. Lawton CA, Brendler C and Rukstalis, D: Management Options for Stage D1 Prostatic Adenocarcinoma, October 1995.

5. Year Book of Oncology: 1995 Edition. Lawton CA, Drobyski W, Ash R, Casper J, et al: Impact of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia, 1995.

6. Year Book of Oncology: 1995 Edition. Lawton CA, Casper J, Camitta B, Truitt R, et al: Unrelated bone marrow donor transplant for children with leukemia or myelodysplasia, September 1995.

7. Current Radiation Oncology, Volume 3. Cohen EP and Lawton CA: Pathogenesis, Prevention and Management of Radiation Nephropathy, E Arnold Ltd. London 1998 pp 94-109.

8. Clinical Radiation Oncology, 1997 Edition: Lawton CA, Associate Editor, Genitourinary section; Senior Editors Leonard Gunderson and Joel Tepper, Churchill Livingstone. Lawton CA, Pisansky T, Lee RW, and Bostwick DG: Prostate Cancer (Chapter 40) 2000, pp762-819.

9. Comprehensive Textbook of Genitourinary Oncology, Second Edition, Nicholas J. Vogelzang Editor. Lawton CA, and Steinberg G. Management Options for Patients with Lymph Node Metastases from Prostate Cancer December 1999.

10. Moss' Radiation Oncology: Rationale, Technique, Results, 8th Edition, James D. Cox, M.D., K Kian Ang MD, PhD, Editors. Lawton, C. A.: Radiation Therapy for Bone Marrow (Stem Cell) Transplant (Chapter 37), 2003, pp 939-953.

11. Clinical Radiation Oncology 2nd Edition, Editors: Leonard Gunderson and Joel Tepper, Prostate Cancer, Kuban D, Potters L, Lawton C, Pisansky T.,(Chapter 50) p1165-1236, Churchill Livingstone, Philadelphia, PA 2007.

12. Moss' Radiation Oncology: Rationale, Technique, Results, 9th Edition, Editors: James D. Cox, M.D., K Kian Ang MD, PhD, Radiation Therapy for Bone Marrow or Stem Cell Transplant: Firat, S, Lawton, C: (Chapter 38) 2010, pp923-1006, Mosby, Philadelphia PA

13. Human Radiation Injury Editors: Shrieve DC, Loeffler JS: Kidney and adrenal toxicity: Lawton CA, Cohen EP, Moulder JE.. Lippincott Williams & Wilkins, Philadelphia PA 2010.

14. The Yearbook of Oncology: Editor in Chief: JamesTate Thigpen, MD: Associate Editors: Robert Arceci, MD, PHD, Thomas Bauer II, MD, Roger Byhardt, MD, Michael Gordon, MD, Colleen Lawton, MD Mosby, Inc, Philadelphia, PA 2009.

15. The Yearbook of Oncology: Associate Editors: Robert Arceci, MD, PHD, Thomas Bauer II, MD, Michael Gordon, MD, Colleen Lawton, MD, James Tate Thigpen, MD Mosby, Inc, Philadelphia, PA 2010.

16. The Yearbook of Oncology: Associate Editors: Robert Arceci, MD, PHD, Thomas Bauer II, MD, E. Gabriela Chiorean, MD, Michael Gordon, MD, Colleen Lawton, MD, Barbara A. Murphy, MD, James Tate Thigpen, MD, Anne S. Tsao, MD, Mosby Inc, Philadelphia, PA 2011.

17. The Yearbook of Oncology: Associate Editors: Robert Arceci, MD, PHD, E. Gabriela Chiorean, MD, Colleen Lawton, MD, Barbara A. Murphy, MD, James Tate Thigpen, MD, Anne S. Tsao, MD, Mosby Inc, Philadelphia, PA 2012 Edition.

18. The Yearbook of Oncology: Associate Editors: Robert Arceci, MD, PHD, E. Gabriela Chiorean, MD, Colleen Lawton, MD, Barbara A. Murphy, MD, James Tate Thigpen, MD, Anne S. Tsao, MD, Mosby Inc, Philadelphia, PA 2013 Edition.

19. Yearbook of Medicine 2014 Editors: James Barker, Jennifer Barton, Kenneth DeVault, Renee Gearick, Michael Gold, Nancy Khardori, Colleen Lawton, Derek LeRoith, Randall Pearson. Elsevier Mosby Philadelphia PA, 2014 Edition

20. Yearbook of Medicine 2015 Editors: James Barker, Jennifer Barton, Kenneth DeVault, Renee Gearick, Michael Gold, Nancy Khardori, Colleen Lawton, Derek LeRoith. Elsevier Mosby Philadelphia PA, 2015 Edition

1. Lawton CA. Reply to Dr. Horst Zincke's letter to the editor regarding article published in Cancer (Is long-term survival possible with external beam irradiation for Stage D1 adenocarcinoma of the prostate? 69:2761-2766, 1992); misrepresentation of survival figures and clarification. Cancer 70:2742-2743, 1992.

2. Wilson JF, Hussey DH, Lawton CA, Leibel SA, Shipley WU: Response to article in The Journal of Family Practice 37:432-436, 1993; Errors in data regarding risks associated with radiation therapy and prostatectomy. Journal of Family Practice 39:216, 1994.

3. Lawton CA. Radiation Oncology. Inter Journal of Rad Onc Biol Phys, 37:2 pp 000-001, 1997.

4. Lawton CA. Node-Positive Prostate Carcinoma. Inter Journal of Rad Onc Biol Phys, 39:3 671-672, 1997,

5. Lawton CA. Commentary, Total Body Irradiation for Bone Marrow Transplantation, Oncology 13:7, p972-982, 1999

6. Lawton CA. Letter to the editor in response to Dr. Millar regarding update of 94-13. Int J Rad Onc Bio Phys 71:1; p 316, May 1, 2008

7. Lawton CA, Bae, K: Second letter to the editor in response to Williams & Willshire regarding update of 94-13. Int J Rad Onc Bio Phys 71:1, p315, May 1,2008

8. Lawton CA. Choosing Wisely Commentary: As good citizens and patients'advocates, we should begin where we can." Practical Radiation Oncology 4(6) 3356-357, 2014.

9. Haffty BG, Lawton CA, Sandler H. Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer. JAMA Oncol. 2015 Aug;1(5):688-9.

1. Colleen A Lawton: Choosing Wisely, Practical Radiation Oncology 4:6, November-December 2014, 356-357.

1. Lawton CA, Glisch C, Byhardt RW, Sehring S, Hartz A, Cox JD: Extended field radiation for prostate carcinoma with para-aortic lymph node metastasis. Presented at the American Radium Society, San Francisco, CA, April 1986.

2. Komaki R, Barber-Derus, SW, Glisch C, Lawton CA, Cox JD: Complications from high-dose paraaortic and pelvic irradiation for malignant genitourinary tumors. Presented at the 72nd Scientific Assembly and Annual Meeting of the RSNA, Chicago, IL, November 1986.

3. Lawton CA, Murray KJ, Casper JT, Ash RC, and Gillin MT: Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant. Presented at ASTRO, New Orleans, LA, October 8 - 14, 1988. Int J Rad Onc Biol Phys Proceedings of the American Society for Therapeutic Radiation and Oncology 30th Annual Meeting 15:S1, p 211, 1988.

4. Casper J, Bunin N, Hunter J, Baxter-Lowe, LA, Murray K, Lawton C, Menitove J, Lum L, Truitt R, Camitta B, Ash R: Unrelated donors for pediatric bone marrow transplantation. Presented at European Society for Paediatric Haematology and Immunology Meeting, July 20, 1989.

5. Casper J, Hunter J, Baxter-Lowe L, Murray K, Lawton C, Menitove J, Lum L, Truitt R, Camitta B, Ash RC: The successful use of unrelated donors for 55 bone marrow transplants. Presented at the International Society of Experimental Hematologists, July 20, 1989.

6. Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT, Moulder JE: Late renal dysfunction in adult survivors of bone marrow transplantation. Presented at the American Radium Society meeting, April 21 - 25, 1990, Scottsdale, AZ.

7. Casper J, Bunin N, Hunter J, Baxter-Lowe LA, Murray K, Lawton C, Menitove J, Truitt R, Camitta B, Ash R: Unrelated donors for pediatric bone marrow transplantation. Presented at "Intravenous Gamma Globulin: Current Role in Bone Marrow Transplant, Malignancy, and Immune Hematologic Disorders" meeting, Scottsdale, AZ, October 10 - 13, 1990.

8. Casper J, Sedmak J, Lauer M, Hunter J, Baxter-Lowe LA, Murray K, Lawton C, Truitt R, Camitta B, Ash R: Intravenous immunoglobulin: Use in pediatric bone marrow transplantation. Presented at "Intravenous Gamma Globulin: Current Role in Bone Marrow Transplant, Malignancy, and Immune Hematologic Disorders" meeting, Scottsdale, AZ, October 10 - 13, 1990.

9. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SRL, Rubin P: Long term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Presented at ASTRO meeting, Miami Beach, FL, October 1990. Int J Rad Onc Biol Phys 19(Suppl 1):199, 1990.

10. *Cooley GM, Lawton CA, Murray KJ, Byhardt R, Wilson JF: Radiation Pneumonitis and Adult Respratory Distress Syndrome in the Postoperative Non-small Cell Carcinoma Patient and Evaluation of Radiotherapeutic Factors and Extent of Surgery. Resident Essay Award Winner, Presented at ASTRO Meeting, Miami Beach FL, October 1990, Int J Rad Onc Biol Phys 19(Supp 1):121, 1990.

11. Cohen EP, Lawton CA, Ash RC, Moulder J, Hunter J: Clinical course of bone marrow transplant nephropathy. Presented at The American Society of Nephrology 23rd Annual Meeting, December 2 - 5, 1990.

12. Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF: Is long term survival possible with external beam irradiation for Stage D1 adenocarcinoma of the prostate? Presented at the American Radium Society meeting, Montreal, Canada, May 4 - 8, 1991.

13. Lawton CA, Fish BL, Moulder JE: Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation. Presented at the 9th International Congress of Radiation Research meeting, Toronto, Canada, July 1991.

14. Lawton CA, Ash RC, Murray KJ, Cohen EP, Barber-Derus SW, Moulder JE, Wilson JF: Influence of renal shielding on the incidence of late renal dysfunction associated with bone marrow transplantation. Presented at the 77th Scientific Assembly and Annual Meeting of RSNA, Chicago, IL, December 1991. Radiology 181(P) p.250, 1991.

15. Casper J, Baxter-Lowe LA, Truitt R, Murray K, Lawton C, Bunin N, Hunter J, Camitta B, Ash R: Unrelated donors for bone marrow transplantation in children. 1991 Keystone Symposia.

16. Casper J, Camitta B, Ash R, Bunin N, Pietryga D, Garbrecht F, Baxter-Lowe LA, Murray K, Lawton C, Truitt R, Keever C, Flomenberg N: Bone marrow transplantation for Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) using alternative donors. American Society of Hematology 34th Annual Meeting, 1992.

17. Datta S, Haasler GB, Byhardt R, Wilson F, Lawton C, Olson L: Surgical resection followed by single course of radiation-A new approach to superior sulcus tumors of the lung. Wisconsin Surgical Society Spring Meeting, La Crosse, WI, April 16 - 17, 1993.

18. Baxter-Lowe LA, Casper J, Flomenberg N, Dinauer D, Camitta B, Drobyski W, Garbrecht F, Pietryga D, Horowitz M, Anderson T, Chitambar C, Hansen C, Lawton C, Bunin N, Keever C, Pierce K, Ash R: Impact of HLA disparity in bone marrow transplantation. AAI/CIS Joint Meeting, May 1993.

19. Pilepich MV, Caplan R, Al-Sarraf M, John M, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Cox JD: Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: The emerging role of PSA in the assessment of outcome. 35th Annual ASTRO Meeting, New Orleans, LA, October 11 - 15, 1993. Int J Rad Onc Biol Phys 27(Suppl 1):246, 1993.

20. *Gore EM, Lipchik RJ, Ash RC, Lawton CA, Pulmonary function changes in long-term survivors of bone marrow transplantation. 35th Annual ASTRO Meeting, New Orleans, LA, October 11-15, 1993. Int J Rad Onc Biol Phys Proceedings of the American Society for Therapeutic Radiation and Oncology 35th Annual Meeting 27:S1, p 185, 1993 .

21. Cohen EP, Lawton CA, Moulder JE, Flomenberg N: Long-term survival with human bone marrow transplant nephropathy (BMT Np). 26th Annual Meeting of The American Society of Nephrology, November 14 - 17, 1993.

22. Lawton CA, Cantrell JE, Derus SWB, Murray KJ, Byhardt RW, Wilson JF: Are racial differences in clinical stage and survival in patients with prostate cancer explained by differences in presenting symptoms? Presented at the 1993 RSNA Meeting, Chicago, IL, November 28 - December 3, 1993. Radiology 189(P), p. 183, 1993.

23. Casper J, Camitta B, Baxter-Lowe LA, Bunin N, Ash R, Pietryga D, Garbrecht F, Murray K, Lawton C, Truitt R, Keever C, Flomenberg N: Bone marrow transplantation (BMT) for childhood acute lymphocytic leukemia (ALL) using unrelated donors. The American Society of Hematology 35th Annual Meeting, St. Louis, MO, December 3 - 7, 1993.

24. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, Drobyski W, Horowitz M, Camitta B, Garbrecht F, Pietryga D, Lawton C, Ash R, Gottschall J: Therapeutic plasma exchange not effective in the management of TTP/HUS following bone marrow transplantation. Presented at The American Society of Hematology 35th Annual Meeting, St. Louis, MO, December 3 - 7, 1993.

25. Datta S, Haasler GB, Byhardt R, Wilson JF, Lawton C, Olson L: Treatment for superior sulcus tumors - A changing concept. The Society of Thoracic Surgeons Meeting, New Orleans, LA, January 31 - February 2, 1994.

26. Byhardt R, Wilson JF, Lawton C, Witt PL, Borden E, Vaickus L, Breitmeyer J, and Chang AY: Phase I trial of recombinant b-Interferon (r-IFNb, R-FRONE,) and radiation therapy (RT) for non-small cell lung cancer (NSCLC). ASCO 30th Annual Meeting, Dallas, TX, May 14 - 17, 1994. Proceedings of ASCO, Jour Clin Onc 13:354, March 1994

27. Byhardt R, Wilson JF, Lawton C, Witt P, Borden E, Vaickus L, Breitmeyer J, and Chang AY: Phase I trial of recombinant b-Interferon (r-IFNb, R-FRONE) and radiation therapy (RT) for non-small cell lung cancer (NSCLC). Presented at 7th World Conference on Lung Cancer, Colorado Springs, CO, June 26 - July 1, 1994.

28. Roach M III, Caplan RJ, Porter A, John M, Scotte-Doggett RL, Sause WT, Lawton CA, Abrams R, Rotman M, Nelson D, and Gallagher MJ: Combined neoadjuvant total androgen suppression (TAS) and external beam irradiation (XRT) delay the time to biochemical relapse (BCR) or clinical failure (CF) compared to radiation alone for locally advanced adenocarcinoma of the prostate: The Radiation Oncology Group (RTOG) phase III randomized trial 8610. Meeting of the American Urological Association, San Francisco, CA, May 1994.

29. Witt PL, Byhardt R, McAuliffe TL, Wilson JF, Irizarry AF, Lawton C, Borden E, Vaickus L, Breitmeyer J, Chang AY: Biological response in a Phase I trial of recombinant interferon- (IFN, R-Frone) and radiation therapy (RT) for non-small cell lung cancer (NSCLC). Serono Symposia, USA, 1994.

30. Lawton CA, Cantrell JE, Derus SWB, Murray KJ, Byhardt RW, Wilson JF: Prostate cancer: Are racial differences in clinical stage and survival explained by differences in symptoms? Urology Digest 1994, (in press).

31. Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, and Cella D: RTOG's first quality of life study - RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Proceedings of the American Society for Therapeutic Radiology and Oncology 36th Annual Meeting, San Francisco, CA, October 2-6, 1994, Int J Rad Oncol Biol Phys 30(Suppl 1):193, 1994.

32. Pietryga D, Casper J, Garbrecht F, Camitta B, Drobyski W, Horowitz M, Lawton C, Keever C, Baxter-Lowe L, Murray K, Pierce K, Cadwallader S, McAuliffe T, Flomenberg N: Haploidentical bone marrow transplantation (BMT) for hematologic malignancies. 36th Annual Meeting of the American Society of Hematology, Nashville, TN, December 2-6, 1994.

33. Grignon D, Caplan R, Sarkar F, Forman J, Mesic J, Abrams R, and Lawton C.: P-53 suppresser gene status as a predictor of outcome in patients with locally advanced prostatic adenocarcinoma (PCa) treated by radiation therapy with and without androgen ablation pre-treatment: A study based on RTOG Protocol 8610. United States-Canadian Academy of Pathology Meeting, Toronto, Canada, March 11-17, 1995.

34. Grignon D, Caplan R, Sakr W, Porter A, Doggett RLS, Abrams R, and Lawton C.: Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa): A study based on RTOG Protocol 8610. United States-Canadian Academy of Pathology Meeting, Toronto, Canada, March 11-17, 1995.

35. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A: Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of RTOG protocol 85-31). Proceedings of American Society of Clinical Oncology Annual Meeting, Los Angeles, CA, May 20-23, 1995. Proceedings of American Society of Clinical Oncology 14, p239, March 1995.

36. Grignon D, Caplan R, Sarkar F, Forman J, Mesic J, Fu K, Abrams R, and Lawton C.: P53 Suppressor Gene Mutations Predict for Failure Following Combined Neoadjuvant Total Androgen Ablation and External Beam Radiation Therapy for Locally Advanced Prostate Cancer: A Study Based on RTOG Protocol 8610. American Urological Association 1995 Annual Meeting, Las Vegas, NV.

37. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, and Porter A: Phase III trial of adjuvant androgen suppression using goserelin in patients with carcinoma of the prostate treated with definitive radiotherapy. 37th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Miami Beach, FL, October 8-11, 1995. Int J Rad Onc Bio Phys, Proceedings of the American Society for Therapeutic Radiology and Oncology,32:S1, p 1888, 1995.

38. Lawton C, Grignon D, Caplan R, Sarkar F, Forman J, Mesic J, Fu K, Abrams R: Abnormal P-53 supressor gene expression predicts for a poorer outcome in patients with locally advanced adenocarcinoma of the prostate treated by external beam radiation therapy with or without pre-radiation androgen ablation: Results Based on RTOG Study 86-10. 37th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Miami Beach, FL, October 8-11, 1995. Int J Rad Oncol Biol Phys 32 (Suppl 1):230, 1995.

39. Grignon D, Won M, Dolan P, Hammond E, Lawton C, Porter A, Shipley W: DNA content as a prognostic indicator in prostate cancer (PCA): A Study Based on RTOG Protocol 8610. Submitted to United States - Canadian Academy of Pathology Meeting, September 1995.

40. Lawton C, Pajack T, Byhardt R, Sause W, Delrowe J, Pilepich M: Androgen Suppression Plus Radiation vs Radiation Alone for Patients with D1 (nP+) Adenocarcinoma of the Prostate. (Results Based on a National Prospective Randomized Trial RTOG 85-31). Presented at 38th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Los Angeles CA October 1996. Int J Rad Onc Biol Phys, Proceedings of the American Society for Therapeutic Radiology and Oncology, 36:S1, p.228, 1996.

41. Pietryga D, Casper J, Margolis D, Camitta B, Garbrecht F, Drobyski W, Horowitz M, Burns W, Juckett M, Rowlings P, Passweg J, Lawton C, Taylor C, Baxter-Lowe L, Murray K, Pierce K, McAuliffe T, Flomenberg N: Bone marrow transplantation (BMT) using genotypically haploidentical donors. Presented at 38th Annual ASH Meeting, Orlando FL, December 6-10, 1996.

42. Grignon D, Winter K, Pajack T, Pilepich M, Byhardt R, Lawton C, et al: Central Review versus Institutional Gleason Grading and its Impact on Phase III Clinical Trial Analysis: A Review of RTOG Protocol #85-31. Submitted to the United States/Canadian Academy of Pathology Annual Meeting 1996.

43. Lawton CA, Cohen EP,, Rhoades JL, Murray KJ, and Moulder JE. Influence of Radiation Dose and Fractionation Schedule on the Incidence of Clinical Bone Marrow Transplant Nephropathy. presented at the Radiation Research Society Meeting May 1997.

44. Byhardt R, Scott C, Sause W, Emami B, Komaki R, Fisher B, Lee J and Lawton C. Response, Toxicity, Failure Patterns and in Five Radiation Therapy Oncology Group (RTOG) Trials of Sequential and/or Concurrent Cheotherapy (CT) and Radiation Therapy (RT) for Locally Advanced Non-small Cell Carcinoma of the Lung (NSCLC) . Presented at the American Society for Therapeutic Radiology and Oncology meeting, October 1997 Orlando, FL. Int J Rad Onc Biol Phys, Proceedings of the American Society for Therapeutic Radiology and Oncology, 39:S2, p.195. 1997

45. Byhardt R, Scott C, Sause W, Emami B, Komaki R, Fisher B, Lee J and Lawton C. Response, Toxicity, Failure Patterns and in Five Radiation Therapy Oncology Group (RTOG) Trials of Sequential and/or Concurrent Cheotherapy (CT) and Radiation Therapy (RT) for Locally Advanced Non-small Cell Carcinoma of the Lung (NSCLC) . Presented at the 8th World Lung Conference 1997.

46. Winter K, Grignon D, Pajack T, Pilepich M, Byhardt R, Lawton C, et al. Subjective Pathology Tumor Grading: Impact on Design and Analysis of Radiation Therapy Oncology Group (RTOG) Prostate Trial 85-31. Presented at the 2nd Joint Meeting Society for Clinical Trials and International Society for Clinical Biostatistics, July 6-10, 1997.

47. Rhoades J, Lawton C, Cohen E, Murray K, Horowitz M, Drobyski W, Caspar J, and Moulder J. Incidence of Bone Marrow Transplant Nephropathy (BMT-Np) After Twice Daily BID Hyperfractionated Total Body Irradiation. Presented at the American Radium Society, April 30 - May 4, 1997.

48. Scott C, Mousas B, Sause W. Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, et al. Intensified Treatment Increases Survival in Patients with Non-Small Lung Cancer (NSCLC) at What Price? A Quality-Adjusted Survival Analysis of Radiation Therapy Oncology Group (RTOG) Chemo-radiation Studies. International Society of Quality of Life Research

49. Bruner, DW, Scott CB, McGowan D, Lawton C, Hanks G, Prestidge B, Gaspar L, Gore E, Asbell A, RTOG. Validation of the Sexual Ajustment Questinnaire (SAQ) in Prostate Cancer Patients Enrolled on RTOG Studies 90-20 and 94-08. Presented at Oncology Nursing Society.

50. Grignon D, Pajack T, Winter K, Pilepich M, Byhardt R, Lawton C, Gallagher M, Mesic J, Roach M, Hanks G, Coughlin C, and Porter A: Central Review vs Institutional Gleason Grading and its Impact on Phase III Clinical Trial Analysis:A Review of RTOG Protocol 85-31. United States and Canadian Acadamy of Pathology Meeting, Toronto, Canada Modern Path 10:77a, Abs #436, 1997.

51. Bruner, DW, Scott CB, McGowan D, Lawton C, Hanks G, Prestidge B, Gaspar L, Gore E, Asbell A, RTOG. Validation of the Sexual Ajustment Questinnaire (SAQ) in Prostate Cancer Patients Enrolled on RTOG Studies 90-20 and 94-08. Presented at the 39th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, October, 1997, Orlando, FL.

52. Lawton C. 114 Total body irradiation for bone marrow transplantation. Int J Rad Onc Biol Phys, 39, Issue 2, S1, p117, 1997.

53. Roach III, M., Lu J., Pilepich M., Asbell S., Mohuidden M., Terry R., Grignon D., Lawton C., and Shipley W.: Predicting Survival, and the Role of Androgen Suppressive Therapy (AST): RTOG Phase III Randomized Prostate Cancer Trials. Proc Am Soc Thera Rad Oncol ASTRO Phoenix AZ Int J Rad Onc Bio Phys 42(1) #106, #177, 1998.

54. Movsas B., Scott, C., Sause, W., Byhardt R., Komaki R., Cox J., Johnson, D., Lawton C., Dar A., Waserman T., Roach M., Lee J., Andras E. The Benefit Treatment Intensification is Age and Histology-Dependent in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC): A Quality-Adjusted Survival Analysis of Radiation Therapy Oncology Group (RTOG) Chemo-Radiation Studies. 40th Annual ASTRO Meeting. Int J Rad Onc Biol Phys, 42:S1, p.203, 1998.

55. Brunner DW., Scott C., McGowan D., Lawton C., Hanks G., Prestidge G., Han S., Gore E., Asbell S., Rotman M., RTOG. Factors Influencing Sexual Outcomes in Prostate Cancer (PC) Patients Enrolled on Radiation Therapy Oncology Group (RTOG) Studies 90-20 and 94-08. Presented at the 5th Annual International Society of Quality of Life Research (ISOQOLR). Baltimore MD Quality of Life Research 7(7) 575, 1998.

56. Bruner, DW, Scott CB, McGowan D, Lawton C, Hanks G, Prestidge B, Gaspar L, Gore E, Asbell A, RTOG. Validation of the Sexual Ajustment Questinnaire (SAQ) in Prostate Cancer Patients Enrolled on RTOG Studies 90-20 and 94-08. Presented at the 40th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, Phoenix AZ Int J Rad Onc Biol Phys 42(1) #156, 202, 1998.

57. Lawton C.Total body irradiation for bone marrow transplantation. Int J Rad Onc Biol Phys, 42, Issue 1, S1, p104, 1998.

58. Lawton C., Winter K., Murray K., Machtay M., Mesic J., Hanks G., Coughlin C., and Pilepich M.. Updated Results of the Phase III (RTOG) Trial 85-31 Evaluating the Potential Benefit of Androgen Deprivation Following Standard Radiation Therapy for Unfavorable Prognosis Carcinoma of the Prostate. Presented at the 35th Annual ASCO Meeting, Atlanta GA, May 15-18, 1999. Proceedings of the American Society of Clinical Oncology, p.311a, 1999.

59. Roach III M., Lu J., Pilepich MV, Asbell SO, Mohuidden M, Terry R, Grignon D, Lawton C, Shipley W: Having a pre-treatment prostate specific antigen (PSA) is associated with an improved disease specific survival (DSS) for men on Radiation Therapy Oncology Group prostate cancer trials. Presented at ASTRO, San Antonio TX, Oct 31-Nov 4, 1999.

60. Scott C., Roach M., Lawton C., Gallagher M., Russell AH, Hanks GE, Coughlin CT,: Q-twist analysis of men treated for prostate cancer with radiation therapy with or without neoadjuvant combined androgen blockade: RTOG 86-10. Presented at Society for Quality of Life Research, (ISOQOL) Barcelone, Quality of Life Research 8(7) #48, 568, 1999.

61. Shipley WU, Lu JD, Pilepich MV, Roach M, Russell AH, Sause W, Rubin P, Lawton CA, and Machtay M. Does Neoadjuvant Hormone Treatment Compromise Subsequent Androgen Suppression in Prostate Cancer Patients who Fail Initial Radiation Therapy: A Secondary Analysis of RTOG 86-10, ASTRO October 22 - 26, 2000, Boston MA. Int J Rad Onc Biol Phys, Proceedings American Society for Therapeutic Radiology and Oncology, 48:S3, p169, 2000.

62. Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, et al. Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-Small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis. Int J Rad Onc Biol Phys, 48, Issue 3, S1, p157-158, 2000.

63. Shipley W, Heydon K, Pilepich M, Roach III M, Machtay M, Masic J, Sause W, Rubin P, and Lawton C. A Secondary Analysis of RTOG 86-10: Does the Extent of Progressions at the Time of Initiating Salvage Hormone Therapy Influence Survival in Patients with Prostate Cancer who Failed Initial Treatment with Irradiation? Proceedings of ASCO J Clin Oncol 20:1, p.182a, 2001.

64. Roach M, Lu JD, Lawton C, Hsu I-C, Machtay M, Seider MJ et al. A phase III trial comparing whole-pelvic (WP) versus prostate only (PO) radiotherapy and neoadjuvant versus adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 94-13. Int J Rad Onc Biol Phys, Proceedings of the American Society of Therapeutic Radiation and Oncology, 51:S3, p3, 2001.

65. Roach M, DeSalvio M, Lawton C, Uhl V, Machtay M, et al. Neoadjuvant Hormonal Therapy with Whole Pelvic Radiotherapy Improves Progression-Free Survival: RTOG 94-13, A Phase III Randomized Trial. Proceedings from Am Soc Clin Oncol (ASCO) May 2002, Orlando FL J Clin Oncol (In Press)

66. Lee WR, Scott C, Lawton C,, et al: Health Related Quality of Life (HRQOL) in Men Treated with Prostate Brachytherapy Alone on RTOG 98-05. Int J Rad Onc Biol Phys, Proceedings of the American Society for Therapeutic Radiology Oncology 54:2, Supp p47, 2002.

67. Pilepich MV, Winter K, Lawton CA, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proceedings of ASCO J Clin Oncol, 22:381 Abs #1530, 2003.

68. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long term results of a Phase III RTOG study 85-31. Int J Rad Onc Biol Phys, Proceedings of the American Society for Therapeutic Radiology and Oncology 57:2 S172, 2003.

69. Lee WR, DeSilvio M, Lawton C, Gillin M, et al: A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Proceedings of ASCO J Clin Oncol 23:397, Abs #4568, 2004.

70. Abdel-Wahab, B Berkey, A Krishan, T O'Brien, E Hammond, M Roach III, C Lawton, M Pilepich, A Markoe, A Pollack: Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Int J Rad Onc Biol & Phys Proceedings of the American Society of Therapeutic Radiology and Oncology, 60:1, S326, 2004

71. M Roach, M DeSilvio, C Thomas, R Valicenti, S Asbel, C Lawton, and W Shipley: Progression free survival (PFS) after whole pelvic (WP) vs "mini-pelvic" (MP) or prostate only (PO) radiotherapy (RT): A subset analysis of RTOG 94-13, a phase III prospective randomized using neoadjuvant and concurrent (N&CHT). Int J Rad Onc Biol & Phys Proceedings of the American Society of Therapeutic Radiation and Oncology, 60:1, S264, 2004.

72. C. Lawton, M. DeSilvio, W. R. Lee, L. Gomella, D Grignon, M. Gillin, G, Morton, T. Pisansky, H. Sandler. Results of a prospective multi-institutional phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. Int J Rad Onc Biol & Phys Proceedings of the American Society of Therapeutic Radiation and Oncology, 60:1, S184, 2004.

73. Li X, Wang JZ, Jursinic P, Lawton C. IMRT Simultaneous Integrated Boost for High-Risk Prostate Cancer. Int J Rad Onc Biol Phys, 60, 1, S1, pS632-S633, 2004.

74. M Roach, M DeSilvio, C Thomas, R Valicenti, S Asbel, C Lawton, and W Shipley: Field size and progression free survival (PFS) after neoadjuvant hormonal therapy (HT) and radiotherapy (RT) for prostate: Secondary analysis of RTOG 94-13. (Submitted to ASCO 2005)

75. M Roach, M DeSilvio, C Thomas, R Valicenti, S Asbel, C Lawton, and W Shipley: Field size and progression free survival (PFS) after neoadjuvant hormonal therapy (HT) and radiotherapy (RT) for prostate: Secondary analysis of RTOG 94-13. (Submitted to ASCO 2005)

76. CA Lawton, M DeSilvio, W Lee, L Gomella, D Grignon, M Gillin, G Morton, T Pisansky, H Sandler Correlating prostate seed implant quality with clinical outcomes for patients treated on RTOG protocol 98-05 (A multi-institutional phase II trial of transrectal ultrasound guided prostate seed implant for localized prostate cancer) Poster, Prostate Symposium, Orlando Fl, Feb 17, 2005.

77. Fleshner N, Keane T, Lawton C, et al: Adjuvant Androgen Deprivation Therapy Offers a "Cure" in Patients with Poor Prognosis Non-metastatic Prostate Cancer. Int J Rad Onc Biol Phys, 63:S1, pS288, 2005.

78. Lawton C, DeSilvio M, Roach III, M, et al: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13. Int J Rad Onc Biol Phys, 63, S1, pS19, 2005.

79. Lawton C, Bae K, Pilepich M, Hanks G, and Shipley W: Long Term Treatment Sequelae Following External Beam Irradiation + Hormonal Manipulation for Adenocarcinoma of the Prostate: Analysis of RTOG Studies 85-31, 86-10, and 92-02. Poster Prostate Cancer Symposium, San Francisco CA, Feb 24, 2006.

80. Taussky D, Bae K, Bahary JP, Roach M, Lawton C, Shipley W, and Sandler H. Does testosterone influence radiation induced toxicity in radiation therapy of the prostate? A secondary analysis of RTOG protocol 9413. Int J Rad Onc Bio & Phs 66:3 Abs #2215, S329, 2006.

81. Hanks GE, Bae K, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz E, Lawton C, Sandler H, and Shipley W. Ten year follow up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Int J Rad Onc Biol Phys, 66, Issue 3, S1, pS13, 2006.

82. Fleshner N, Keane T, Lawton C, et al: Is Adjuvant Androgen Deprivation Therapy a Treatment of Curative Intent? Presented at Societe Internationale Urologie (SIU) meeting Nov 12-16,2006, Cape Town.

83. Lee W, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Greven K, Kuettel M, Sandler H. Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019.Int J Rad Onc Biol Phys, 66, Issue 3, S1, pS57, 2006.

84. Peng C, Kainz K, Lawton C, Li XA.A comparison of daily megavoltage CT and ultrasound imaging guided radiation therapy for prostate cancer. Int J Rad Onc Bio & Phs 69:3 Abs #2967,S744, 2007.

85. Ritter M, Forman J, Kupelian P, Petereit D, Lawton C, et al:A phase I/II trial of dose-per-fraction escalation for prostate cancer.Int J Rad Onc Bio Phys 69:3 Abs #1066, S174 2007.

86. Morrow N, Erickson B, Lawton C, Li A: Determining margins for organs at risk to account for anatomic motion. Int J Rad Onc Bio & Phs 69:3 Abs #2956, S737, 2007

87. Michalski J, Lawton C, El-Naqa I, et al: Variation in the definition of Clinical Target Volumes for postoperative conformal radiation therapy of prostate cancer. Int J Rad Onc Bio Phs 69:3 Abs #2222, S326, 2007.

88. Lawton C, Michalski J, El-Naqa I, et al: Variation in the definition of Clinical Target Volumes for pelvic node conformal radiation therapy of prostate cancer. Int J Rad Onc Bio Phs 69:3 Abs #2224, S327, 2007.

89. El-Naqa I, Michalski J, Lawton C, et al: Investigation of statistical methods to analyze target volume definition among experts in radiotherapy treatment planning. Presented at 9th Biennial ESTRO Meeting on Physics and Radiation Technology for Clinical Radiotherapy, Barcelona, Sept 8-13,2007.

90. Peng C, Ahunbay E, Godley An, Lawton C, Li X: PTV Margin to account for Deformation during Prostate IGRT. Int J Rad Onc Bio Phs 72:1 Abs #2896, S570, 2008.

91. Roach M, Bae Km Lawton C, Donnelly BJ, Grignon D, Hanks G, Porter A, Lepor H, Venketesan V, Sandler H: Base line serum testosterone (BST) and outcomes among men treated on RTOG 92-02 and RTOG 94-13 for clinically localized prostate cancer. Submitted to GU Symposium at ASCO 2009

92. Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks GE, Porter A, Lepor H, and Sandler H: Impact of Ultrlight Baseline PSA Levels on Biochemical and Clinical Outcomes in on Two Radiation Therapy Oncology Group (RTOG) Prostate Clinical Trial. Proceedings of ASCO J Clin Oncol 27:15S, Abs #5123, 2009

93. Colleen A. Lawton, Daniel Hunt, W Robert Lee, Leonard Gomella, David Grignon, Michael Gillin, Gerard Morton, Thomas Pisansky, and Howard Sandler: Long Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05). Int J Rad Onc Biol & Phs Supplement 75:3 Abs #25, S12, 2009.

94. Mark Ritter, Jeffrey Forman, Patrick Kupelian, Colleen Lawton, and Daniel Petereit: A phase I/II trial of increasingly hypofractionated radiation therapy for prostate cancer. Int J Rad Onc Biol & Phs Supplement 75:3 Abs #170, S80, 2009.

95. Dian Wang, Alex Ho, Amy Trentham-Dietz, Colleen Lawton, Jean B. Owen, J. Frank Wilson Results of Patterns of Care Survey of Patients reated with Radiotherapy for Prostate Cancer in Wisconsin: Comparison to a National Survey. Int J Rad Onc Biol & Phs Supplement 75:3 Abs #2702, S497, 2009.

96. William Shipley, Daniel Hunt, Himu Lukka, Pierre Major, Niall Heney, David Grignon, Maltibehn Patel, Jean-Paul Bahary, Colleen Lawton, and Howard Sandler: Initial report of RTOG 96-01. A phase III trial in prostate cancer: Anti-androgen therapy (AAT) with Bicalutamide during and after radiation therapy (RT). Oral presentation at ASTRO, San Diego CA 1030-11/3/2010. Int J Rad Onc Biol & Phs Supplement 78:3S, Abs #58, S27, 2010.

97. Cury F, Hunt D, Roach III, M, Lawton C, et al: Correlation between PSA response after hormone therapy and treatment outcomes in patients treated on RTOG 94-13.Presented at ASTRO 2010. Int J Rad Onc Biol & Phs Supplement 78:3S Abs #264, S124, 2010

98. Lawton CA, Yan Y, Lee WR, et al: Long Term Results of an RTOG Phase II Trial (00-19) of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate. Presented at ASTRO 2010. Int J Rad Onc Biol & Phs Supplement 78:3S Abs #168, S78, 2010

99. Owen J, Ho A, Wang D, Trenham-Dietz A, Lawton C, and Wilson JF: Measuring Quality of Care for Prostate Cancer Patients in Wisconsin: A Prognostic Risk Model. Academy 2010 Annual Research Meeting, Boston MA, Academy Health Research Meeting Booklet; Abs 839 p143, 2010.

100. William Shipley, Daniel Hunt, Himu Lukka, Pierre Major, Niall Heney, David Grignon, Maltibehn Patel, Jean-Paul Bahary, Colleen Lawton, and Howard Sandler:RTOG 96-01. A phase III trial of Anti-androgen therapy (AAT) with Bicalutamide with salvage radiation therapy (RT)in pT2-3, pNO prostate cancer patients with elevated PSA levels after surgery. Presented at SUO Meeting Bethesda MD 12/8/2010

101. Bradley J, Lawton C, Driscoll C, Li XA, and Wang D: Prospective study of simultaneous integrated boost for high risk prostate cancer using IG-IMRT: Acute toxicity report. Presented at ASTRO, Oct 30 - Nov 4, 2010, San Diego CA. Int J Rad Onc Biol & Phs Supplement 78:3S Abs #2392, S379, 2010.

102. Semenenko V, Guang-Pei C, Lawton CA, Li XA: Dosimetric Comparisons between Monaco and TomoTherapy Treatment Planning Systems for Prostate IMRT Planning. Submitted to the AAPM meeting.

103. Ritter MA, Forman JD, Kupelian PA, Petereit DG, Lawton CA, Chappell, RJ, Tomé WA: Five-year efficacy and toxicity outcomes from a Phase I/II Trial of increasingly Hypofractionated Radiation Therapy for Prostate Cancer Int J Rad Onc Biol & Phys 81:2 Supplement Abs #198 S99 2011.

104. Yang C, Lin F, Cheng E, Lawton C, Wang D, Schultz C, Firat S, Erickson B, Li AX: Using an online adaptive replanning tool for offline adaptive radiotherapy Int J Rad Onc Biol & Phys 81(2) Supplement Abs #3340 S850 2011.

105. Rose CM, Lawton CA, Efstathiou A, et al: Developing a National Radiation Oncology Registry (NROR): A Radiation Oncology Institute (ROI) Initiative. Int J Rad Onc Biol & Phys 81(2) Supplement Abs #3010 S693, 2011

106. Natalya Morrow, Colleen Lawton, Sharon Qi, and X. Allen Li: Impact of Daily Image Quality on Image Guided Radiotherapy for Prostate Cancer Int J Rad Onc Biol & Phys 81(2) Supplement Abs #119 S60 2011

107. Hamstra DA, Dignam J, Porter A, Hanks G, Lawton C, Roach M, Sandler H: Surrogate end-points for prostate cancer specific survival: Superiority of the interval to biochemical failure:An analysis of RTOG 92-02 and 94-13. Int J Rad Onc Biol & Phys 81(2) Supplement Abs #205 S103 2011.

108. FL Cury, D Hunt, M Roach III, C Lawton, E Gore, I Hsu, RE KrischMJ Seider, H Sandler, W Shipley; PSA response after short-term hormonal therapy plus external beam radiotherapy and outcome in patients treated on RTOG 94-13. (Submitted to ASCO 2012)

109. M Roach III, Y Yan, C Lawton, R Lustig, MJ Seider, C Jones, M Rottman, K Zeitzer, M Werner-Wasik, H Kim, C Thomas, and H Sandler; RTOG 94-13 primary update analysis ASCO Meeting Abstract 30:5 supp Feb 2 2012:96

110. C Lawton, S Shook, M Smith, P Tripp, AB Shah, A Martin, H Kim, P Tai, M Duclose; RTOG 05-18 A phase II randomized trial to evaluate the efficacy of Zometa for the prevention of osteonecrosis and associated fractures in patients receiving radiation therapy and long-term (Lutenizing hormone-releasing hormone) LHRH agonist for high-grade and/or locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics 84:3S Abs2402, S369, 2012 Poster Presentation at ASTRO, Boston, MA

111. X. Allen Li, Chengliang Yang, Feng Liu, Ergun Ahunbay, Ester Chang, Chris Schultz, Dian Wang, Selim Frat, Beth Erickson, Colleen Lawton, Combined online and offline adaptive radiation therapy. Int J Rad Onc Biol & Phys 84:3S Abs #71 S29, 2012

112. Feng Liu, Ergun Ahunbay, Esther Chang, Colleen Lawton, X. Allen Li: Dosimetric Benefits of Online Adaptive Replanning for Radiotherapy of Prostate plus Seminal Vesicle: Evaluation Based on Cumulative Dose. Int J Rad Onc Biol & Phys 84:3S Abs #3564 S806-S807, 2012.

113. J Efstathiou, D Nassif, R Chen, K Hoffman, D Kuban, C Lawton, J Michalski, L Potters, C Rose, H Sandler, W Suh, T Wall, A Zeitman, J Bekelman. National Radiation Oncology Registry: The Pilot Prostate Cancer REgistry. Poster ASCO Quality Care Symposium Dec 4, 2012:267.

114. M. Roach III, D. Hunt, Lawton CA, I. C. J. Hsu, R. A. Lustig, C. U. Jones, M. Rotman, K. L. Zeitzer, M. Werner-Wasik, H. Kim, C. R. Thomas Jr., W. U. Shipley, H. M. Sandler;Radiation therapy oncology group (RTOG) 9413: A randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) & neoadjuvant hormonal therapy (NHT) to adjuvant hormonal therapy (AHT) Int Journ Rad Onc Biol & PHys 87:2S Abs #260, S106, 2013

115. DP Lindsay, JR Kharofa, CA Lawton, KA Bylow, P Langenstroer, W See, D Wang: Toxicities and survival of elderly patients with muscle-invasive bladder cancer treated with devinitive bladder preservation therapy Int Journ Rad Onc Biol & Phys 87:2S Abs 2506, S398, 2013.

116. G Chen, A Tai, F Liu, C Lawton, XA Li: Optimizing CT acquisition for prostate cancer radiation treatment planning and delivery. Int Journ Rad Onc Biol & Phys 87:2S Abs #3524, S709, 2013

117. Xinfeng Chen, Phillip Prior, Eric Paulson, Colleen Lawton, Allen Li: IMRT planning of prostate cancer for a MR-Linac based on MRI only. Poster presented at AAMP July 2014.

118. Hurwitz MD, Zang Q, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, et al: Adjuvant Radiation Therapy, Androgen Deprivation and Docetaxel for High-Risk Prostate Cancer Post-protatectomy: Results of RTOG 06-21. Int Journ Rad Onc Biol & Phys 901S, Abs #CT-01, S2, 2014. Presented at ASTRO, San Francisco Sept 13-17, 2014.

119. Lawton CA, Dignam J, Hanks GE, Lepor H, Grignon D, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Kwok Y, Roach III M, Lin X, and Sandler H: Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Updates of NRG Oncology/RTOG 9202. (Accepted for oral presentation ASTRO 2015)

120. Currey AD, Mac O, Denson S, Rehm J, Denson K, and Lawton C, Development of a Geriatrics Curriculum for Radiation Oncology Residents. (Poster presentation ASTRO 2015)

121. Kainz K, Lawton C, and Li XA: Burst-modulated arc therapy with flattening-filter-free beams versus flattening-filtered beams ed to AAPM 57th Annual Meeting, Anaheim, CA July 12-16, 2015.

122. Chen X, Dalah E, Prior P, Lawton C, and Li XA:MRI-based planning: dosimetric feasibility of dose painting for ADC-defined intra-prostatic tumor. AAPM 57th Annual Meeting, Anaheim CA, July 12-16, 2015

123. Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CA, Efstathiou JA, Kudchadker RJ,Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M III, Pinover WH, Beyer DC, Sandler HM, Kachnic LA: Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating 2 ultrahypofractionated regimens (UHR) for prostate cancer(CaP) Poster presentationto GU Cancer Symposium ASCO January 7, 2016

124. Shipley WU,Seiferheld W,lukka HR, Major PP MD, Heney NM, Grignon DJ, Sartor O,Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng F,Lovett RD, Balogh AG, Souhami L, Rosenthal SA,Kerlin KJ, Sandler HM,NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA Presented at GU ASCO January 7, 2016

125. Thompson JR, Kilari DK, Erickson B, Lawton CA, Chemotherapy and radiation for vaginal or urethral recurrence of urothelial carcinoma after radical cystectomy. Genitourinary Cancer Symposium Feb 16-18, 2017

126. S Lim, E Ahunbay, J Zhang, Lawton C, XA Li. Practical considerations for online replanning during SBRT of prostate cancer. (Submitted to 2017 ASTRO)

127. Hall, WA, Eastwood, D, Kilari, D, Van Wickle, J, Raychaudhuri, R, Borkenhagen, J, See, W, Lawton, C; Androgen Deprivation Therapy (ADT) and Radiation Therapy (RT) Alone As Compared with Trimodality Therapy With ADT, RT, and Surgery In Men With High Risk, Non-Metastatic Adenocarcinoma Of The Prostate; Int J Radiat Oncol Biol Phys, September, 2017

128. Kainz K, Lim SN, Chen GP, Lawton CA, Siker ML, Firat S, Robbins JR, Erickson BA, Li A. Initial Clinical Experience with Using an Automated Dose Tracking Tool to Verify Dose Delivery and Trigger Adaptive Replanning. Submitted to 2017 ASTRO Annual Meeting, 09/24-09/27/17. San Diego, CA

129. Hall WA, Karrison TG, Rosenthal SA, Amin M, Gomella LG, Purdy J, Sartor O, Michalski M, Garzotto M, Bergom C, Jani A, Lawton C, Simko J, Moore J, Gore E, Lee WR, Nguyen P, Danielson B, Sandler H, Feng F. The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521. Presented at 2018 Annual ASTRO Meeting, 10/21/18-10/24/18. San Antonio, TX

130. Hall W, Liu S, Fishbane N, Xu M, Davicioni E, Mahal B, Den R, Dess R, Jackson W, Wong A, Schaeffer E, Karnes R, Carroll P, Nguyen P Lawton C, Spratt D, Feng F. Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment. Presented at 2018 Annual ASTRO Meeting, 10/21/18-10/24/18. San Antonio, TX

131. Hall WA, Karrison T, Rosenthal SA, Amin M, Gomella LG, Purdy J, Sartor AO, Michalski J, Garzotto M, Bergom C, Jani AB, LAWTON CAF, Simko JP, Moore J, Gore E, Lee WR, Nguyen PL, Danielson B, Sandler HM, Feng FF. The Influence of the Pretreatment Host Immune State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521. 2020

132. Hall W, Paulson E, Davis B, Spratt D, Dearnaley D, Efstathiou J, Jani A, Buyyounouski M, Pisansky T, Tran P, Chen R, Cury F, Michalski J, Rosenthal S, Koontz B, Wong A, Tree A, Nguyen P, Feng F, Sandler H, LAWTON C. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volume For Intact and Post-Operative Prostate Cancer. Oral Abstract presented at 62nd Annual Meeting, October 25-28, 2020.

133. Bero EH, Rein L, Banerjee A, Straza MW, LAWTON CAF, Schultz CJ, Erickson BA, Siker ML, and Hall WA. Characterization of Underrepresented Populations in Modern Era Radiation Therapy Clinical Trials. Oral Poster Presentation at 2020 ASTRO Virtual Meeting. October 18-21, 2020

134. Chen GP, Tai A, Puckett L, Lim SN, Keiper T, Gore EM, Johnstone C, LAWTON CAF, Li A. Clinical Implementation of Real-time Motion Tracking with Jaws and MLC during Helical Tomotherapy Delivery. Eposter presentation at 2020 ASTRO Virtual Meeting. October 18-21, 2020

135. Chen RC, Karrison T, LAWTON CAF, Hall WA, Borno HT, Rosu-Bubulac M, Jani AB, Schuster DM, Seider M, Efstathiou JA, Posadas EM, Nguyen PL, Feng FY. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. Volume 39, Issue 6_suppl; Meeting Abstract; 2021 Genitourinary Cancers Symposium Feb 11-13 2021; Poster presentation.

136. Cooper B, Bedi M, Bovi J, Currey A, Erickson B, Gore E, Hall W, Lawton C, Schultz C, Siker M, Saeed H. Enhancing Patient-Physician Experience in the Digital Era: A Review of Mobile Health Applications for Oncology Patients. Accepted for poster presentation at the American Society for Radiation Oncology (ASTRO) 63rd Annual Meeting, October, 2021, Chicago, IL.

137. Chan E, Pugh SL, Simko J, Feng FY, Shipley WU, Lukka H, Bahary JP, Pisansky TM, Zeitzer KL, LAWTON CA, Efsathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong AC, Dess RT, McGinnis S, Kuettel MR, Demora L, Sandler HM. Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601. Journal of Clinical Oncology. Volume 40, Issue 6_suppl; Meeting Abstract; 2022 ASCO Genitourinary Cancers Symposium Feb 17-19 2022

138. Sritharan K, Akhiat H, Cahill D, Choi S, Choudhury A, Chung P, Diaz J, Dysager L, Hall W, Kerkmeijer L, LAWTON CA, Murray J, Nyborg C, Pos FJ, Rigo M, Schytte T, Sidhom M, Sohaib A, Tan A, van der Voort van Zyp J, Vesprini D, Zelefsky MJ, Tree A. Determining interobserver variability in prostate bed CTV target delineation using MRI. Abstract submitted to ESTRO May 2022. Accepted for Poster Discussion: 14: Urology 2; May 8, 2022, Copenhagen.

139. Chen X, Paulson E, Ahunbay E, Omari E, Hall W, LAWTON C, Straza M, Li XA. A simple adaptive planning workflow for MR-guided radiotherapy of prostate cancer. Abstract submitted to AAPM.

140. Sarah Emma, Anjishnu Banerjee, Shravya Jastia, Jochem R.N. van der Voort van Zyp, Jasmijn M. Westerhoff, Lois A. Daamen, Floris J. Pos, John P Christodouleas, Ananya Choudhury, Uulke A. van der Heide, Colleen A.F. Lawton, Michael Straza, Meena Bedi, Eric Paulson, Haidy Nasief, Allen Li, H.M. Verkooijen, Alison Tree, William A. Hall, MD. Intra-treatment Radiomic Features Acquired Using a 1.5 Tesla MR Linear Accelerator Correlate with Future Patient Reported Quality of Life. Abstract submitted for 2023 ASTRO